# Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis

> **NCT00737100** · PHASE2 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 510 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** Placebo Respimat
- **DRUG:** Tiotropium bromide 5 mcg
- **DRUG:** tiotropium bromide-low dose-2.5mcg

## Key facts

- **NCT ID:** NCT00737100
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-09
- **Primary completion:** 2010-04
- **Final completion:** —
- **Target enrollment:** 510 (ACTUAL)
- **Last updated:** 2014-05-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00737100

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00737100, "Safety and Efficacy of 12-wk Treatment With Two Doses of Tiotropium Respimat in Cystic Fibrosis". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00737100. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*